All of the findingsreported above clearly indicate SHP2 as animportant molecular target for cancer and RASopathies.25,26 Research efforts in SHP2-targeted drug discovery have long beenfocused mainly on active-site inhibitors,27,28 which however are affected by a lack of target specificity.26,2729. This evidence concerns the gene PTPN11 and RASopathy.